2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/1on664om2hmh1.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T74a8,

Summary Table

Category	Details
Risk Factors	Recent pharyngitis or skin infection (post-streptococcal), young males (IgA nephropathy), family history of renal disease or deafness (Alport syndrome), systemic autoimmune disease (SLE), pulmonary hemorrhage with renal failure (Goodpasture syndrome)
Etiology	Inflammatory damage to the glomerular basement membrane (GBM) and/or mesangium caused by immune complex deposition, anti-GBM antibodies, or pauci-immune vasculitis
Patient Presentation	"Cola-colored" or "smoky" urine (hematuria), decreased urine output, periorbital or facial edema (especially in the morning), weight gain from fluid retention
Classic Physical Exam	Hypertension, periorbital edema, signs of fluid overload (pulmonary crackles, peripheral edema), possible skin rash or joint findings if systemic disease is present
Key Diagnostic Results	Urinalysis: dysmorphic RBCs and RBC casts (pathognomonic); proteinuria typically $< 3.5\ g/day$; elevated BUN and creatinine; low complement (C3) in post-streptococcal GN, lupus nephritis, and MPGN
Management	Supportive care (salt and fluid restriction, loop diuretics, antihypertensives) for post-streptococcal GN; immunosuppression (corticosteroids, cyclophosphamide, rituximab) for RPGN, lupus nephritis, and Goodpasture syndrome; plasmapheresis for Goodpasture syndrome and certain RPGN subtypes
Keywords	"Cola-colored urine," "RBC casts," "low complement," "pharyngitis 2 weeks ago," "skin infection 3-6 weeks ago," "crescents on biopsy," "linear IgG on IF," "mesangial IgA deposits," "anti-GBM antibodies," "ANCA positive"

1. Pathophysiology

Nephritic syndrome is fundamentally a disease of glomerular inflammation. Unlike nephrotic syndrome, where the primary problem is a permeability defect in the filtration barrier, nephritic syndrome results from an inflammatory insult that damages the glomerular capillary wall, allowing red blood cells and moderate amounts of protein to leak into the urine.

The inflammation can be triggered by three broad mechanisms. The first is immune complex deposition, where circulating antigen-antibody complexes become trapped in the glomerulus (as in post-streptococcal GN or lupus nephritis) or form in situ when antibodies bind to antigens already planted in the glomerular structures. This activates the complement cascade, which recruits neutrophils and macrophages that release proteases and reactive oxygen species, directly injuring the GBM and endothelial cells. This is why many forms of nephritic syndrome present with low serum complement levels, and this finding is heavily tested.

The second mechanism is anti-GBM antibody disease (Goodpasture syndrome), in which autoantibodies target the type IV collagen (alpha-3 chain) in the basement membrane. Because this same collagen is found in the pulmonary alveolar basement membrane, patients classically present with the combination of glomerulonephritis and pulmonary hemorrhage. On immunofluorescence, these antibodies deposit in a smooth, continuous pattern described as linear IgG staining, which is a hallmark finding.

The third mechanism is pauci-immune vasculitis, driven by anti-neutrophil cytoplasmic antibodies (ANCA). Here, immunofluorescence shows little to no immune deposits ("pauci-immune"), and the damage is caused by direct neutrophil-mediated injury to the vessel wall. This category includes granulomatosis with polyangiitis (GPA, c-ANCA/PR3) and microscopic polyangiitis (MPA, p-ANCA/MPO).

The downstream consequences of this inflammation explain the clinical presentation. Damaged glomeruli allow RBCs to pass through gaps in the GBM, producing hematuria. Because RBCs are squeezed through these irregular openings, they become dysmorphic and can aggregate into RBC casts within the tubular lumen. The inflammatory damage also reduces the glomerular filtration rate (GFR), leading to oliguria and azotemia (rising BUN and creatinine). Reduced GFR triggers sodium and water retention through activation of the renin-angiotensin-aldosterone system (RAAS), producing hypertension and edema. Proteinuria occurs but is typically in the sub-nephrotic range ($< 3.5\ g/day$), because the damage is inflammatory rather than a pure permeability defect.

2. Classification and Clinical Manifestation

Subtype	Mechanism	Classic Patient	Key Clinical Features	Immunofluorescence Pattern	Complement Levels
Post-Streptococcal GN (PSGN)	Immune complex (subepithelial "humps")	Child, 1-3 weeks after pharyngitis or 3-6 weeks after impetigo	Cola-colored urine, periorbital edema, hypertension	Granular ("starry sky") IgG and C3	Low C3, normal C4
IgA Nephropathy (Berger Disease)	Mesangial IgA deposition	Young male, 1-2 days after URI or GI illness	Episodic gross hematuria concurrent with infection	Mesangial IgA deposits	Normal
Rapidly Progressive GN (RPGN) Type I	Anti-GBM antibodies (Goodpasture)	Young male smoker	Hemoptysis + hematuria (pulmonary-renal syndrome)	Linear IgG	Normal
RPGN Type II	Immune complex	Varies (lupus, PSGN, IgA, MPGN)	Depends on underlying cause	Granular	Low (if lupus or PSGN)
RPGN Type III	Pauci-immune (ANCA-associated vasculitis)	Middle-aged to elderly	Sinusitis, pulmonary nodules (GPA), or isolated renal involvement (MPA)	Negative/pauci-immune	Normal
Lupus Nephritis (Class IV, Diffuse Proliferative)	Immune complex	Young woman with SLE	Nephritic features + systemic lupus manifestations (rash, arthritis, serositis)	"Full house" (IgG, IgA, IgM, C3, C1q)	Low C3 and C4
Membranoproliferative GN (MPGN)	Immune complex or complement-mediated	Older child or young adult, association with Hepatitis B/C	Mixed nephritic-nephrotic features, "tram-track" appearance on biopsy	Granular	Low C3 (persistently)
Alport Syndrome	Genetic defect in type IV collagen	Young male with family history	Sensorineural hearing loss, ocular abnormalities, progressive renal failure	Absent or irregular staining for type IV collagen	Normal
Henoch-Schonlein Purpura (IgA Vasculitis)	IgA-mediated small vessel vasculitis	Child after URI	Palpable purpura (buttocks/legs), abdominal pain, arthralgia, hematuria	Mesangial IgA (identical to IgA nephropathy)	Normal

3. Diagnostic Workup

Test	Purpose	Expected Finding in Nephritic Syndrome
Urinalysis (Best Initial Test)	Detect hematuria, proteinuria, casts	Dysmorphic RBCs, RBC casts, mild-to-moderate proteinuria
Serum BUN/Creatinine	Assess renal function	Elevated (azotemia)
Complement levels (C3, C4)	Narrow differential	Low C3: PSGN, lupus, MPGN. Low C3 and C4: lupus. Normal: IgA, anti-GBM, ANCA
ASO titer / Anti-DNase B	Confirm recent streptococcal infection	Elevated in PSGN
Anti-GBM antibodies	Diagnose Goodpasture syndrome	Positive
ANCA (c-ANCA, p-ANCA)	Diagnose ANCA-associated vasculitis	c-ANCA (PR3): GPA; p-ANCA (MPO): MPA, EGPA
ANA, Anti-dsDNA, Anti-Smith	Evaluate for lupus nephritis	Positive in SLE
Serum IgA	Support IgA nephropathy diagnosis	Elevated in ~50% of cases
Renal biopsy (Gold Standard)	Confirm histologic diagnosis and guide treatment	Light microscopy, immunofluorescence, and electron microscopy findings vary by subtype

The best initial test for any patient suspected of nephritic syndrome is a urinalysis with microscopy. The hallmark finding is the presence of RBC casts, which are considered pathognomonic for glomerulonephritis and localize the bleeding to the glomerulus rather than the lower urinary tract. Dysmorphic RBCs further support a glomerular origin. Proteinuria will be present but typically in the sub-nephrotic range. If proteinuria exceeds $3.5\ g/day$, consider overlap with nephrotic syndrome (as seen in MPGN, diffuse proliferative lupus nephritis, or advanced IgA nephropathy).

After confirming the nephritic picture, the next step is to determine the underlying cause using serologic testing. The single most important branching point in the workup is the complement level. This divides nephritic syndrome into two camps:

Low complement narrows the differential to PSGN, lupus nephritis (Class III or IV), and MPGN. If a child presents 1 to 3 weeks after a sore throat with low C3 and an elevated ASO titer, PSGN is the diagnosis and no biopsy is needed if the clinical picture is classic. In adults with low C3 and C4 plus positive ANA and anti-dsDNA, lupus nephritis is the leading diagnosis. In MPGN, the C3 is persistently low (unlike PSGN, where C3 normalizes within 6 to 8 weeks).

Normal complement points toward IgA nephropathy, anti-GBM disease, and ANCA-associated vasculitis. IgA nephropathy classically presents with gross hematuria occurring within 1 to 2 days of an upper respiratory infection (this short latency is a key discriminator from PSGN). Anti-GBM disease is suspected when there is concurrent pulmonary hemorrhage. ANCA testing distinguishes GPA (c-ANCA/anti-PR3) from MPA (p-ANCA/anti-MPO).

Renal biopsy is the most accurate (gold standard) test and is indicated when the diagnosis is uncertain, when RPGN is suspected (rapidly rising creatinine over days to weeks), or when histologic classification will change management (as in lupus nephritis, where the ISN/RPS class determines therapy). Biopsy results are interpreted using three modalities: light microscopy (cellular proliferation, crescent formation), immunofluorescence (pattern and type of immune deposits), and electron microscopy (location of deposits: subepithelial, subendothelial, mesangial).

A critical teaching point: in RPGN, do not delay biopsy. Crescents on biopsy (proliferation of parietal epithelial cells in Bowman's space) indicate severe, potentially irreversible damage. The percentage of glomeruli with crescents correlates with prognosis and urgency of treatment.

4. Management and Treatment

Subtype	Acute Management	Long-Term Management	Notes
PSGN	Supportive: sodium/fluid restriction, loop diuretics (furosemide 1-2 mg/kg/day), antihypertensives if needed	Self-limited in children; monitor proteinuria and complement normalization	Antibiotics (penicillin) treat existing infection but do not prevent PSGN
IgA Nephropathy	ACE inhibitor or ARB (e.g., enalapril 5-20 mg/day or losartan 50-100 mg/day) for proteinuria reduction and BP control	Corticosteroids if proteinuria persists $> 1\ g/day$ despite 3-6 months of optimized RAAS blockade; consider SGLT2 inhibitors	Fish oil (omega-3 fatty acids) historically used; evidence is mixed
Goodpasture Syndrome (Anti-GBM)	Plasmapheresis (daily for 2-3 weeks) + pulse IV methylprednisolone (500-1000 mg/day x 3 days) followed by oral prednisone (1 mg/kg/day) + cyclophosphamide (2 mg/kg/day for 2-3 months)	Taper steroids over 6-9 months; monitor anti-GBM titers	Dialysis-dependent patients with 100% crescents on biopsy have poor prognosis and may not benefit from immunosuppression
ANCA-Associated Vasculitis (GPA/MPA)	Induction: pulse IV methylprednisolone + rituximab (375 mg/m$^2$ weekly x 4) OR cyclophosphamide (15 mg/kg IV every 2-4 weeks)	Maintenance: rituximab or azathioprine (2 mg/kg/day) for at least 18-24 months; taper steroids	Plasmapheresis may be added in severe cases (creatinine > 5.7 mg/dL or pulmonary hemorrhage)
Lupus Nephritis (Class III/IV)	Induction: pulse IV methylprednisolone (1000 mg/day x 3 days) then oral prednisone (1 mg/kg/day) + mycophenolate mofetil (2-3 g/day) or IV cyclophosphamide	Maintenance: mycophenolate mofetil (1-2 g/day) + low-dose prednisone; hydroxychloroquine is continued in all lupus patients	Mycophenolate mofetil is preferred over cyclophosphamide for induction in many guidelines due to a more favorable side effect profile
MPGN	Treat underlying cause (Hepatitis C: direct-acting antivirals; Hepatitis B: entecavir/tenofovir)	Immunosuppression if idiopathic and progressive	Complement-mediated (C3 glomerulopathy) may respond to eculizumab

For PSGN, the critical concept is that this condition is self-limited, especially in children. Treatment is purely supportive. Loop diuretics (furosemide) manage fluid overload and hypertension. Antihypertensives (calcium channel blockers or hydralazine acutely) are used if blood pressure remains elevated. Antibiotics are given only if active streptococcal infection is still present, but they do not alter the course of the glomerulonephritis. Prognosis is excellent in children; adults have a higher risk of progression to chronic kidney disease. The complement level (C3) should normalize within 6 to 8 weeks; failure to do so should prompt reconsideration of the diagnosis (think MPGN or C3 glomerulopathy).

For IgA nephropathy, first-line therapy is RAAS blockade with an ACE inhibitor or ARB. This reduces intraglomerular pressure and proteinuria, which is the strongest modifiable risk factor for progression. If proteinuria remains above 1 g/day despite optimized RAAS blockade for 3 to 6 months, a course of corticosteroids (e.g., the TESTING protocol: methylprednisolone 0.4 g/day IV x 3 days at months 1, 3, 5 with oral methylprednisolone in between) may be considered. SGLT2 inhibitors (dapagliflozin 10 mg/day) have emerged as an important adjunctive therapy for proteinuric kidney disease, including IgA nephropathy (supported by the DAPA-CKD trial and EMPA-KIDNEY data).

For RPGN of any type, the guiding principle is that crescentic GN is a renal emergency. Delay in treatment leads to irreversible scarring and end-stage renal disease. The approach depends on the underlying mechanism (Type I, II, or III). All severe cases receive pulse IV corticosteroids followed by a cytotoxic agent. Plasmapheresis is critical in anti-GBM disease because it physically removes the pathogenic antibodies from the circulation. In ANCA-associated vasculitis, rituximab has become the preferred induction agent in many centers based on the RAVE and RITUXVAS trials, with equivalent efficacy and a more favorable safety profile compared to cyclophosphamide.

For lupus nephritis, biopsy classification (ISN/RPS) drives treatment. Class I and II (minimal or mesangial) need no immunosuppression beyond general lupus management. Class III and IV (focal and diffuse proliferative) require aggressive induction followed by maintenance. Class V (membranous) may overlap with nephrotic syndrome and is treated with immunosuppression if proteinuria is significant. Hydroxychloroquine should be continued in all patients with lupus nephritis, as it reduces flares and improves renal survival. Importantly, cyclophosphamide is contraindicated in pregnancy; mycophenolate is also teratogenic (Category D). If a woman of childbearing age requires treatment, azathioprine is the safest option among conventional immunosuppressants.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Nephrotic Syndrome	Both cause edema, proteinuria, and abnormal urinalysis	Nephrotic: proteinuria $\geq 3.5\ g/day$, hypoalbuminemia, hyperlipidemia, fatty casts, no RBC casts. Nephritic: hematuria with RBC casts, sub-nephrotic proteinuria, hypertension, azotemia
Urinary Tract Infection (UTI) or Cystitis	Both can present with hematuria	UTI: WBC casts and positive urine culture, dysuria, frequency; no dysmorphic RBCs or RBC casts
IgA Nephropathy vs. PSGN	Both follow an upper respiratory infection and cause hematuria	Latency period: IgA = 1-2 days ("synpharyngitic"); PSGN = 1-3 weeks. IgA: normal complement; PSGN: low C3. IgA: mesangial IgA on IF; PSGN: granular IgG/C3 with subepithelial humps on EM
Henoch-Schonlein Purpura vs. IgA Nephropathy	Identical renal biopsy (mesangial IgA)	HSP has extrarenal features: palpable purpura on buttocks/lower extremities, abdominal pain, arthralgia. IgA nephropathy is renal-limited
Goodpasture Syndrome vs. GPA	Both can cause pulmonary-renal syndrome (hemoptysis + GN)	Goodpasture: linear IgG on IF, anti-GBM antibodies, normal complement. GPA: pauci-immune on IF, c-ANCA/anti-PR3 positive, upper airway involvement (sinusitis, saddle nose, nasal crusting)
Lupus Nephritis vs. PSGN	Both have low complement and granular IF pattern	Lupus: low C3 and C4, positive ANA/anti-dsDNA, "full house" IF (IgG, IgA, IgM, C3, C1q), systemic features. PSGN: low C3 only (C4 normal, classical pathway not primarily involved), ASO titer elevated, granular IgG/C3 only
Thin Basement Membrane Disease (Benign Familial Hematuria)	Presents with persistent microscopic hematuria	Thin BMD: isolated hematuria with no proteinuria, no hypertension, no renal dysfunction, normal complement. Biopsy shows diffusely thin GBM without immune deposits
Alport Syndrome vs. Thin BMD	Both present with hematuria and GBM abnormalities	Alport: progressive renal failure, sensorineural hearing loss, ocular abnormalities (anterior lenticonus), X-linked inheritance pattern, irregular GBM with "basket-weave" splitting on EM

6. Traps and High-Yield Pearls

The most common mistake students make with nephritic syndrome questions is confusing the timeline of hematuria onset after an upper respiratory infection. When a vignette describes hematuria occurring 1 to 2 days after a pharyngeal illness, many students reflexively choose PSGN because they associate "sore throat then hematuria" with streptococcal disease. However, the correct answer is IgA nephropathy. PSGN requires a latency period of at least 1 to 3 weeks (pharyngitis) or 3 to 6 weeks (skin infection) for immune complexes to form and deposit. IgA nephropathy, by contrast, causes hematuria concurrently or within days of the mucosal infection because the IgA immune response is immediate. This distinction is tested repeatedly.

A second common trap involves complement levels. Students must memorize that low complement narrows the differential to only three conditions: PSGN, lupus nephritis, and MPGN. Everything else (IgA nephropathy, Goodpasture, ANCA vasculitis, Alport) has normal complement. Furthermore, within the low-complement group, the pattern matters: PSGN has low C3 with normal C4 (alternative pathway), while lupus nephritis has low C3 and low C4 (classical pathway activation by immune complexes containing C1q).

A third high-yield trap is the immunofluorescence pattern. Linear IgG staining is Goodpasture and only Goodpasture. Granular ("lumpy-bumpy") staining indicates immune complex deposition (PSGN, lupus, MPGN). Pauci-immune (negative IF) means ANCA-associated vasculitis. "Full house" staining (all immunoglobulin classes plus complement) is essentially diagnostic of lupus nephritis. Test-writers frequently include IF results in the vignette stem and expect you to immediately narrow the diagnosis.

Finally, students often miss that RPGN is a clinical emergency, not a histologic curiosity. If a vignette describes rapidly declining renal function over days to weeks with RBC casts, the next best step is renal biopsy (to classify the crescentic GN and guide immunosuppressive therapy), not conservative management or observation. Delaying biopsy in this setting is the wrong answer. The percentage of crescents on biopsy directly correlates with the urgency and intensity of treatment, and once crescents become fibrotic (sclerosed), the damage is irreversible.

The core competency being tested in nephritic syndrome questions is the ability to use clinical context clues (timeline, complement levels, serologies, and IF patterns) to identify the correct subtype and then match it to the appropriate management, whether supportive (PSGN) or emergent immunosuppression (RPGN).

1d:["$","$L2c",null,{"article":{"id":"593bf611-25c2-4531-a02a-35fde92aaf3f","title":"Sindrom Nefritik","content":"$2d","category":"Uronefrologi","created_at":"2026-09-05T11:46:02.831339+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]